GENEVA (AP) — Drug maker Novartis will cut 1,960 jobs in the United States this year in anticipation of lower sales for two of its hypertension drugs, the Swiss company said Friday.
Basel-based pharmaceutical giant Novartis AG said the cuts will affect 1,630 sales positions in the field and 330 posts at its U.S. headquarters in New Jersey.
The restructuring was necessary because of the expiry of its patent for the best-selling hypertension drug Diovan and the failure of a clinical study into another hypertension drug, Tekturna, Novartis said.
“We recognize that the next two years will be challenging in the Pharmaceuticals Division and we are proactively making these changes to further focus our pipeline on the best opportunities and align our market position on our growth brands,” the head of Novartis’ pharmaceuticals division, David Epstein, said in a statement.Read more on NewsOK.com
Read more
0